Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences (FBRX) EBITDA Margin (2016 - 2020)

Forte Biosciences (FBRX) has disclosed EBITDA Margin for 5 consecutive years, with 1361.11% as the latest value for Q1 2020.

  • Quarterly EBITDA Margin rose 19072778.0% to 1361.11% in Q1 2020 from the year-ago period, while the trailing twelve-month figure was 7214.95% through Dec 2020, up 18355661.0% year-over-year, with the annual reading at 176341.67% for FY2019, 17607030.0% down from the prior year.
  • EBITDA Margin for Q1 2020 was 1361.11% at Forte Biosciences, up from 117955.56% in the prior quarter.
  • The five-year high for EBITDA Margin was 1800.0% in Q3 2016, with the low at 217811.11% in Q4 2018.
  • Average EBITDA Margin over 5 years is 90272.59%, with a median of 99490.0% recorded in 2017.
  • The sharpest move saw EBITDA Margin crashed -20830916bps in 2019, then soared 19072778bps in 2020.
  • Over 5 years, EBITDA Margin stood at 1616.67% in 2016, then plummeted by -6822bps to 108680.0% in 2017, then crashed by -100bps to 217811.11% in 2018, then skyrocketed by 46bps to 117955.56% in 2019, then soared by 101bps to 1361.11% in 2020.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 1361.11%, 117955.56%, and 208311.11% for Q1 2020, Q4 2019, and Q3 2019 respectively.